2-(3-chloropropoxy)quinoline | 1147328-95-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-(3-chloropropoxy)quinoline
• CAS: 1147328-95-7
• 化学式: C₁₂H₁₂ClNO
• 分子量: 221.686
• InChiKey: MAQLAURHIDSERO-UHFFFAOYSA-N

物化性质

• 沸点：
  347.3±17.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6,7-二甲氧基-1,2,3,4-四氢异喹啉 、 2-(3-chloropropoxy)quinoline 在 sodium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以26%的产率得到2-(3-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)propoxy)quinoline
  参考文献：
  名称：

  Activity–lipophilicity relationship studies on P-gp ligands designed as simplified tariquidar bulky fragments

  摘要：

  A series of alkyloxyquinoline derivatives has been developed to evaluate the relationship between P-gp potency and lipophilicity. The results show a satisfactory lipophilicity-activity correlation although a series of derivatives showing higher P-gp potency is needed in order to confirm this hypothesis. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.019
• 作为产物：
  描述：

  2-喹啉醇 、 1,3-二氯丙烷 在 sodium hydride 作用下， 以 甲苯 为溶剂， 反应 0.25h， 以41%的产率得到2-(3-chloropropoxy)quinoline
  参考文献：
  名称：

  Activity–lipophilicity relationship studies on P-gp ligands designed as simplified tariquidar bulky fragments

  摘要：

  A series of alkyloxyquinoline derivatives has been developed to evaluate the relationship between P-gp potency and lipophilicity. The results show a satisfactory lipophilicity-activity correlation although a series of derivatives showing higher P-gp potency is needed in order to confirm this hypothesis. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.019

文献信息

• Derivatives of quinoline as inhibitors for MEK
  申请人：AstraZeneca AB

  公开号：EP1584619A1

  公开（公告）日：2005-10-12

  1. A compound of formula (I) or a pharmaceutically acceptable salt thereof. wherein: n is 0-1; X and Y are independently selected from -NH-, -O-, -S-, or -NR8- where R8 is alkyl of 1-6 carbon atoms and X may additionally comprise a CH2 group; R7 is a group (CH2)mR9 where m is 0,or an integer of from 1-3 and R9 is a substituted aryl group, an optionally substituted cycloalkyl ring of up to 10 carbon atoms, or an optionally substituted heterocyclic ring or an N-oxide of any nitrogen containing ring; R6 is a divalent cycloalkyl of 3 to 7 carbon atoms, which may be optionally further substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a divalent pyridinyl, pyimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally further substituted with one or more specified groups; R1, R2, R3 and R4 are each independently selected from hydrogen or various specified organic groups. Compounds are useful as pharmaceuticals for the inhibition of MEK activity.

  化合物的化学式（I）或其药用盐。其中：n为0-1；X和Y分别选择自-NH-、-O-、-S-或-NR8-，其中R8为1-6个碳原子的烷基，X还可以包括一个CH2基团；R7为( )mR9基团，其中m为0或1-3的整数，R9为取代芳基、最多含有10个碳原子的环烷基环、或者取代的杂环环，或者任何含氮环的N-氧化物；R6为3到7个碳原子的二价环烷基，可以选择地进一步取代为一个或多个1到6个碳原子的烷基基团；或者为二价吡啶基、嘧啶基或苯基；其中吡啶基、嘧啶基或苯基可以选择地进一步取代为一个或多个特定基团；R1、R2、R3和R4分别独立选择自氢或各种指定的有机基团。这些化合物可用作抑制MEK活性的药物。
• QUINOLINE DERIVATIVES AS INHIBITORS OF MEK ENZYMES
  申请人：AstraZeneca AB

  公开号：EP1178967B1

  公开（公告）日：2006-03-08
• [EN] QUINOLINE DERIVATIVES AS INHIBITORS OF MEK ENZYMES<br/>[FR] DERIVES QUINOLINE INHIBITEURS D'ENZYMES MEK
  申请人：ASTRAZENECA AB

  公开号：WO2000068201A1

  公开（公告）日：2000-11-16

  A compound of formula (I) or a pharmaceutically acceptable salt thereof wherein: n is 0-1; X and Y are independently selected from NH-, -O-, -S-, or NR8- where R8 is alkyl of 1-6 carbon atoms and X may additionally comprise a CH¿2? group; R?7¿ is a group (CH¿2)mR?9 where m is 0, or an integer of from 1-3 and R9 is a substituted aryl group, an optionally substituted cycloalkyl ring of up to 10 carbon atoms, or an optionally substituted heterocyclic ring or an N-oxide of any nitrogen containing ring; R6 is a divalent cycloalkyl of 3 to 7 carbon atoms, which may be optionally further substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a divalent pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally further substituted with one or more specified groups; R¿1?, R2, R3 and R4 are each independently selected from hydrogen or various specified organic groups. Compounds are useful as pharmaceuticals for the inhibition of MEK activity.